Neurizon inks $1.5M loan against R&D Tax Rebate
Neurizon Therapeutics (ASX:NUZ) retreated in intra-day trade on Wednesday after inking a non-dilutive loan agreement for $1.5 million to fund its current and future operations seeking to treat Huntington’s with its flagship drug NUZ-001.The funds in question are secured against it...
Currently unlisted.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
DUO | Eulogy | 17/10/16 | 55 | 28K | |||
|
|||||||
DUO | ASX Code and Company Name Changes 2016 | 22/02/16 | 23 | 15K | |||
|
|||||||
DUO | Monday 15th | 21/02/16 | 125 | 36K | |||
|
|||||||
DUO | Ann: Acquisition of Zyber Secure Mobile Solutions Completed | 20/02/16 | 95 | 40K | |||
|
|||||||
DUO | Trading begins as ZYB on 22nd of Feb | 18/02/16 | 0 | 1.2K | |||
|
|||||||
DUO | Zyber Presentation Breakdown | 17/02/16 | 162 | 34K | |||
|
|||||||
DUO | Clay Epstein and the board | 17/02/16 | 40 | 11K | |||
|
|||||||
DUO | Ann: Initial Director's Interest Notice | 17/02/16 | 5 | 3.4K | |||
|
See All Discussions